Takeda Pharmaceutical Company Ltd
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Study to Gather Information About Overall Occurrence and New Cases of Dravet and Lennox-Gastaut Syndromes in Children, Teenagers and Adults in Spain
- Conditions
- Dravet Syndrome (DS)Lennox-Gastaut Syndrome (LGS)
- Interventions
- Other: No intervention
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 237
- Registration Number
- NCT05982717
- Locations
- 🇪🇸
Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain
🇪🇸H. Universitario Infantil Niño Jesús, Madrid, Spain
🇪🇸H. Universitario La Paz, Madrid, Spain
An Absorption, Distribution, Metabolism, Excretion (ADME) Study of [14C]Subasumstat in Adults With Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Takeda
- Target Recruit Count
- 3
- Registration Number
- NCT05976334
- Locations
- 🇭🇺
Central Hospital of Northern Pest - Military Hospital, Budapest, Hungary
🇭🇺Pharmaceutical Research Associates Magyarorszag, Budapest, Hungary
A Study of TAK-279 in Adults With or Without Liver Damage
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Takeda
- Target Recruit Count
- 27
- Registration Number
- NCT05976321
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸American Research Corporation - Texas Liver Institute, San Antonio, Texas, United States
A Database Survey of Comparison The Risk of Haemorrhage Between Vortioxetine Tablet Treatment and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment in Participants With Depression
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 147777
- Registration Number
- NCT05932407
- Locations
- 🇯🇵
Takeda Selected Site, Tokyo, Japan
A Study of Maribavir Pediatric Formulation in Healthy Adult Participants
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 32
- Registration Number
- NCT05918822
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
- Conditions
- Alpha1-Antitrypsin Deficiency
- Interventions
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2025-02-27
- Lead Sponsor
- Takeda
- Target Recruit Count
- 37
- Registration Number
- NCT05899673
- Locations
- 🇺🇸
UF Clinical and Translational Science Institute, Gainesville, Florida, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸UAB Hospital Clinical Research Unit, Birmingham, Alabama, United States
A Study About Fazirsiran in People With and Without Liver Problems
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 34
- Registration Number
- NCT05891158
- Locations
- 🇭🇺
CRU Hungary Kft, Kistarcsa, Hungary
🇸🇰Summit Clinical Research s.r.o., Nove Zamky, Slovakia
A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Takeda
- Target Recruit Count
- 26
- Registration Number
- NCT05886478
- Locations
- 🇩🇪
Universitätsmedizin Göttingen, Göttingen, Germany
🇫🇷Hopital Saint Andre, Bordeaux, France
🇫🇷Hopital Saint Louis, Paris, France
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 53
- Registration Number
- NCT05886491
- Locations
- 🇺🇸
Tri-Star BMT/Sarah Cannon Nashville, Nashville, Tennessee, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, United States
A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan
- Conditions
- Multiple Myeloma
- Interventions
- Other: No Intervention
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- Takeda
- Target Recruit Count
- 330
- Registration Number
- NCT05882279
- Locations
- 🇯🇵
Takeda selected site, Tokyo, Japan